Browse >
Home /
Uncategorized / Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Patient Value
Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Patient Value
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company's major product Aricept(R) (donepezil hydrochloride tablets) to further contribute to patients with Alzheimer's disease. As progress in those programs has been made, Eisai announces the status as follows: 1.
DISCLAIMER: Warning! Warning! We are NOT medical doctors and don't even play them on TV. We're just ordinary people reporting on health developments as we hear about them. None of the statements on this website has been evaluated by the FDA. Furthermore, none of the statements on this website should be construed as dispensing medical advice or making claims regarding the cure of diseases. You should always consult a licensed health care professional before starting any supplement, dietary, or exercise program, especially if you are pregnant or have any pre-existing injuries or medical conditions. FURTHERMORE: If you purchase any product through our emails or via this website, we may earn a sales commission. We review and promote products about natural health... so we definitely have a conflict of interest. Any results we tell you about are DEFINITELY not typical and we can't guarantee that any product you find through our website or emails will make a damn bit of difference in your life... so, buyer beware! In fact, many products do not work at all! You could waste hundreds of dollars on products and not see a single change in your health. Sorry, but that's just the reality. Read the promos we tell you about and make up your own mind. No promises and definitely no guarantees!